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Purpose: Previous studies have reported that anemia increased mortality in patients with 
COPD. However, it is unclear whether anemia is associated with increased COPD mortality 
in the general population. The purpose of our study is to identify whether anemia is related to 
long-term mortality in COPD using a large population-based database.
Patients and methods: Using the National Health Insurance Service-Health Screening Cohort, 
we identified COPD patients with available hemoglobin level. We analyzed mortality among 
patients with COPD from 2003 to 2013 according to hemoglobin level.
Results: A total of 7,114 patients with COPD were identified. Mean age was 65.0±9.3 years, 
and 62.9% were male. Anemia was present in 469 patients (6.6%). The overall mortality rate 
was 46.5% in anemia and 32.1% in non-anemia groups (p,0.001). The hazard ratio of anemia 
for mortality was 1.31 (95% CI, 1.11–1.54). Among patients with anemia, the hemoglobin level 
correlated well with mortality.
Conclusion: Anemia was associated with increased long-term mortality of COPD, and even 
mild anemia was related to a significantly increased risk.
Keywords: COPD, mortality, anemia, hemoglobin
Introduction
COPD was the third leading cause of death worldwide in 2010.1 Mortality in patients 
with COPD is related to various measures, including forced expiratory volume in 
1 second, ratio of inspiratory to total lung capacities, exercise capacity, dyspnea scores, 
body mass index (BMI), and exacerbation frequency.2
Anemia is a well-known comorbidity of COPD. The prevalence of anemia in COPD 
ranges from 7.5% to 32.7%.3 Anemia reflects chronic illness and burden of disease, 
and COPD patients with anemia have an increased risk for poor outcomes. Previous 
studies have reported that anemia increased mortality in COPD;4–9 however, these stud-
ies only included patients who were receiving long-term oxygen therapy or required 
hospitalization or analyzed a small number of patients or short-term survival. To the 
best of our knowledge, no large-scale and population-based studies have evaluated 
the effect of anemia on the long-term survival of COPD.
The purpose of our study was to identify whether anemia is related to long-term 
mortality in COPD using a large population-based database. We also aimed to evaluate 
whether the degree of anemia affects the survival of patients with COPD.
Materials and methods
source of data
Since 2000, the National Health Insurance Service (NHIS) in Korea has provided a 
health insurance service to nearly all people living in Korea. Consequently, a large 
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amount of health-related data has accumulated in the NHIS 
system. Using this database, the Korean NHIS has established 
a research database. Because all Koreans have been recom-
mended to undergo a national health screening every 2 years, 
the NHIS was able to generate a health screening cohort that 
was the NHIS-Health Screening (NHIS-Heals) database. 
From 2002 to 2003, a total of 5,150,000 people between the 
ages of 40 and 79 years received national health screening. 
Among them, 514,866 people were sampled and followed up 
from 2002 to 2013 for a research database, which was used 
for our study (Figure 1). NHIS-Heals database comprised a 
random selection of 10% (n=514,866) of all health screening 
participants (n=5,150,000) in 2002 and 2003. This research 
database included data on socioeconomic status (household 
income), medical treatments, medical care institutions, and 
general health examinations. NHIS data is de-identified by 
government. This study was approved by the Institutional 
Review Board of NHIS Ilsan Hospital.
study population
Because the NHIS database did not include spirometry 
data essential for the diagnosis of COPD and did not also 
include an individual’s medical history or symptoms, 
we identified COPD patients using the International 
Classification of Disease-Tenth Revision (ICD-10) and 
prescription details in the health screening cohort. We 
used the diagnostic criteria that an individual should 
visit the medical facility at least twice per year with 
both a COPD diagnostic code and a prescription for 1 or 
more COPD medications. Similar to previous studies,10–13 
COPD patients were identified by the presence of all of 
the following criteria: .40 years of age; ICD-10 codes 
for COPD (J43-J44, except J430); and COPD medication 
use at least twice per year. COPD medications include 
long-acting muscarinic antagonist, long-acting beta-2 
agonist (LABA), inhaled corticosteroid (ICS), ICS plus 
LABA, short-active muscarinic antagonist (SAMA), 
short-acting beta-2 agonist (SABA), SAMA plus SABA, 
methylxanthines, systemic corticosteroids, and systemic 
beta agonists. The national health screening cohort 
included laboratory data, from which we obtained the 
hemoglobin levels. Hemoglobin status was categorized 
as anemia or non-anemia according to the World Health 
Organization guidelines (anemia defined as hemoglobin 
,12 g/dL in females, ,13 g/dL in males).14 The popula-
tion with COPD or anemia in 2002 was excluded, and 
only patients with newly diagnosed COPD from 2003 to 
2005 were enrolled. We followed these COPD patients 
from 2003 to 2013 to analyze the effect of anemia on 
COPD survival (Figure 1). All Koreans have been rec-
ommended to undergo a national health screening every 
2 years; therefore, all individuals had 1 or 2 hemoglobin 
NHIS-Heals data
(N=5,150,000, 40≤ age ≤79, from 2002
to 2003)
1. ICD-10 code for COPD
2. COPD medication more than twice
per year
514,866 were sampled for a research
database
COPD population with anemia (n=469)
→ followed up from 2003 to 2013
Identified new COPD patients during
2003–2005 (n=7,114)
COPD population without anemia (n=6,645)
→ followed up from 2003 to 2013
Washed out COPD
or anemia patients in
2002
Figure 1 Flow chart of the study population.
Abbreviations: ICD-10, International Classification of Disease-Tenth Revision; NHIS-Heals, National Health Insurance Service-Health Screening.
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measurements from 2003 to 2005. If an individual had 
2 measurements, we used the first hemoglobin result.
Determinants of disease and 
demographic factors
The demographic factors of COPD patients were analyzed 
at the time of COPD diagnosis and first health screening 
visits. Socioeconomic status was divided into 5 categories 
according to household income. Charlson comorbidity index 
(CCI) was calculated according to a previous study.15 BMI 
was calculated based on height and body weight. The patients 
were categorized as underweight (BMI,18.5), normal 
(18.5–22.9), overweight (23–24.9), obese I (25.0–29.9), or 
obese II ($30).16 Smoking status was divided into 3 groups 
according to a health questionnaire completed at the first 
health screening visit. Never-smokers were defined as those 
who answered that they had never smoked. Ex-smokers were 
defined as those who answered that they had smoked before, 
but did not smoke at the time of the health screening visit. 
Current smokers were defined as those who answered that 
they smoked at the time of the health screening visit.
study outcomes
Patients were enrolled at the time of COPD diagnosis and 
followed up until the end of the study period or death. The 
monthly mortality was compared between anemic and non-
anemic groups from 2003 to 2013. We also analyzed the 
effect of different hemoglobin levels on mortality.
statistical analysis
Differences between groups were assessed using the 
Chi-square test for categorical variables and Student’s t-test 
for continuous variables. A Cox proportional hazards model 
was used to identify independent variables for mortality 
of COPD. Results were presented as hazard ratio (HR) 
and 95% CI. Violation of proportional hazards assump-
tion was tested by exploring log (-log [survival]) curves. 
A p-value ,0.05 was considered statistically significant. All 
statistical analyses were performed with the SAS program, 
version 9.4 (SAS Institute, Cary, NC, USA).
Results
study population
A total of 7,114 patients with COPD were included during 
the period 2003 to 2005 (Table 1). Mean age was 65.0±9.3 
years, and 62.9% were male. Anemia was present in 469 
(6.6%) patients. Gender distribution was similar between 
anemia and non-anemia groups, but elderly patients were 
more frequent in the anemic group. Mean hemoglobin level 
was 11.5±1.1 g/dL in the anemia group and 14.2±1.2 g/dL 
in the non-anemia group. Anemic patients had higher CCI 
and lower BMI. Overall, patients in the anemia group were 
older and more likely to have chronic illness than those in 
the non-anemia group.
Mortality
The overall mortality rate during the study period was 46.5% 
in the anemia group and 32.1% in the non-anemia group. The 
mean follow-up duration was 100.0±36.5 months (87.7±39.9 
in anemia vs 100.8±36.1 in non-anemia). Table 2 showed a 
Cox proportional hazards model for factors associated with 
mortality in COPD patients. In multivariate analysis, overall 
mortality was associated with old age, low socioeconomic 
status, high CCI, low BMI, and anemia. The HR of anemia for 
mortality was 1.31 (95% CI, 1.11–1.54). Lower hemoglobin 
Table 1 Demographic and clinical characteristics of COPD 
patients with or without anemia
Variable Anemia
(n=469)
Non-anemia
(n=6,645)
p-value
Male 291 (62.1) 4,185 (63.0) 0.686
age (years) 67.8±8.6 64.8±9.3 ,0.001
40–49 21 (4.5) 552 (8.3)
50–59 51 (10.9) 1,154 (17.4)
60–69 172 (36.7) 2,666 (40.1)
$70 225 (48.0) 2,273 (34.2)
hemoglobin (mg/dl) 11.5±1.1 14.2±1.2 ,0.001
household income 0.064
,20% 120 (25.6) 1,328 (20.0)
20%–39% 78 (16.6) 1,133 (17.1)
40%–59% 69 (14.7) 1,040 (15.7)
60%–79% 90 (19.2) 1,351 (20.3)
$80% 112 (23.9) 1,793 (27.0)
CCI ,0.001
1 112 (23.9) 2,437 (36.7)
2 171 (36.5) 2,501 (37.6)
3 128 (27.3) 1,192 (17.9)
$4 58 (12.4) 515 (7.8)
BMI (kg/m2) ,0.001
,18.5 88 (18.9) 182 (6.9)
18.5–22.9 203 (43.5) 994 (37.7)
23.0–24.9 80 (17.1) 648 (24.6)
25.0–29.9 87 (18.6) 734 (27.8)
$30.0 9 (1.9) 81 (3.1)
smoking 0.109
never 303 (67.5) 1,584 (62.9)
ex 45 (10.0) 328 (13.0)
Current 101 (22.5) 608 (24.1)
Deaths 218 (46.5) 2,132 (32.1) ,0.001
Note: Data are shown as the mean ± sD or number (%).
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index.
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levels were also associated with increased mortality regard-
less of anemia severity. The HR for death in patients with 
a hemoglobin value between 11.0 and 13.0 g/dL compared 
with a hemoglobin value over 13.0 g/dL was 1.23 (95% 
CI, 1.04–1.45). Patients with hemoglobin ,7 g/dL had an 
approximately 5-fold higher risk of death than non-anemic 
patients. Figure 2 shows the Kaplan–Meier survival curves 
for anemia and non-anemia. The survival rate of anemia 
group was lower than that of the non-anemia group. The 
5-year survival rate was 0.72 in the anemia group and 0.84 
in the non-anemia group. Figure 3 shows the data for dif-
ferent hemoglobin levels. These show a clear difference 
in survival rate according to hemoglobin. Even in anemia 
patients, the decrease in hemoglobin level was closely 
related to the decrease in survival rate. When we analyzed 
the HR for mortality using continuous hemoglobin values 
(g/dL), the HR of hemoglobin for mortality was 0.92 (95% 
CI, 0.86–0.96).
Discussion
To the best of our knowledge, this is the first study that evalu-
ated the long-term effect of anemia on COPD survival in the 
general population. Our data showed that the prevalence of 
anemia in COPD was 6.6% and that anemia was associated 
with increased long-term mortality. Hemoglobin level was 
well correlated with mortality. Even a mild decrease in hemo-
globin increased the risk of death, and the risk of mortality 
increased in proportion to the decrease in hemoglobin.
Although anemia is a well-known comorbidity of COPD, 
studies on the impact of hemoglobin on COPD mortality are 
Table 2 Cox proportional hazards model for factors associated with mortality in COPD patients
Variable Univariate Multivariate (anemia) Multivariate (hemoglobin)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
anemia 1.69 (1.47–1.95) ,0.001 1.31 (1.11–1.54) 0.002 – –
hemoglobin (mg/dl)
$13.0 1 – – 1
11.0–12.9 1.17 (1.02–1.36) 0.031 – – 1.23 (1.04–1.45) 0.017
9.0–10.9 1.57 (1.10–2.25) 0.014 – – 1.62 (1.10–2.39) 0.014
7.0–8.9 3.48 (1.97–6.16) ,0.001 – – 2.74 (1.53–4.88) 0.001
,7.0 5.09 (1.27–20.35) 0.022 – – 5.12 (1.25–20.97) 0.023
Female 0.44 (0.40–0.48) ,0.001 0.48 (0.41–0.57) ,0.001 0.44 (0.36–0.53) ,0.001
age (years)
40–49 1 1 1
50–59 2.74 (1.77–4.23) ,0.001 3.18 (1.57–6.42) 0.001 3.19 (1.58–6.45) 0.001
60–69 7.97 (5.31–11.95) ,0.001 7.89 (4.07–15.32) ,0.001 7.88 (4.05–15.30) ,0.001
$70 19.25 (12.87–28.81) ,0.001 18.77 (9.70–36.33) ,0.001 18.86 (9.77–36.52) ,0.001
household income
,20% 1 1 1
20%–39% 0.90 (0.79–1.02) 0.115 0.90 (0.74–1.10) 0.322 0.90 (0.74–1.10) 0.310
40%–59% 0.79 (0.69–0.91) 0.001 0.77 (0.62–0.96) 0.019 0.76 (0.61–0.95) 0.016
60%–79% 0.80 (0.71–0.91) 0.001 0.79 (0.65–0.96) 0.020 0.79 (0.65–0.97) 0.022
$80% 0.84 (0.75–0.94) 0.003 0.82 (0.68–0.99) 0.035 0.82 (0.68–0.98) 0.032
CCI
1 1 1 1
2 1.07 (0.97–1.18) 0.181 1.09 (0.97–1.28) 0.261 1.09 (0.93–1.27) 0.274
3 1.37 (1.22–1.53) ,0.001 1.22 (1.01–1.47) 0.042 1.20 (1.00–1.45) 0.057
$4 2.04 (1.78–2.35) ,0.001 1.33 (1.03–1.71) 0.027 1.34 (1.04–1.72) 0.023
BMI (kg/m2)
,18.5 1 1 1
18.5–22.9 0.45 (0.38–0.53) ,0.001 0.54 (0.45–0.57) ,0.001 0.54 (0.45–0.65) ,0.001
23.0–24.9 0.28 (0.23–0.34) ,0.001 0.42 (0.34–0.53) ,0.001 0.43 (0.34–0.53) ,0.001
25.0–29.9 0.21 (0.17–0.26) ,0.001 0.34 (0.27–0.43) ,0.001 0.35 (0.28–0.44) ,0.001
$30.0 0.12 (0.07–0.23) ,0.001 0.27 (0.15–0.51) ,0.001 0.27 (0.15–0.50) ,0.001
smoking
never 1 1 1
ex 1.47 (1.22–1.78) ,0.001 1.07 (0.88–1.30) 0.500 1.08 (0.89–1.31) 0.466
Current 1.40 (1.20–1.62) ,0.001 1.03 (0.88–1.21) 0.676 1.03 (0.88–1.21) 0.684
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; hr, hazard ratio.
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lacking, and the characteristics of populations in previous 
studies were highly variable. Overall, studies have shown a 
trend for increased mortality in COPD patients with anemia. 
However, most studies had retrospective designs, included 
patients who were receiving long-term oxygen therapy or 
required hospitalization, or analyzed a small number of 
patients or short-term survival. Overall, previous studies 
might be categorized into 3 broad groups: COPD patients 
with long-term oxygen therapy or non-invasive ventilation; 
stable COPD outpatients; and hospitalized COPD patients 
with acute exacerbation.
The pivotal study analyzing the long-term effect of anemia 
on COPD mortality was conducted by Chambellan et al.4 They 
used the ANTADIR (Association Nationale pour le Traitement 
a Domicile de l’Insuffisance Respiratoire) database, which 
was generated from the French national home-care system for 
patients requiring oxygen support or mechanical ventilation. 
Among COPD patients receiving long-term oxygen therapy, 
the prevalence of anemia was 12.6% in men and 8.2% in 
women. The hematocrit was an independent predictor of 
survival, hospital admission rate, and cumulative duration of 
hospitalization in this population. The long-term survival rate 
decreased with lower hematocrit levels. Kollert et al analyzed 
similar patients who had severe COPD and chronic respiratory 
failure with non-invasive ventilation.17 They reported that 
high hemoglobin level prior to the initiation of non-invasive 
ventilation was associated with better long-term survival. The 
optimal cutoff value for prediction of death was 14.3 g/dL for 
females and 15.1 g/dL for males.
The effect of anemia on mortality for stable COPD outpa-
tients has also been reported. Cote et al reported hemoglobin 
level and its clinical impact for stable COPD outpatients in 
a USA Veterans Administration pulmonary clinic.18 The 
number of total COPD patients was 683, and anemia was 
present in 116 (17%). Anemia was independently associated 
with increased dyspnea and reduced the 6-minute walking 
distance; however, it was not a significant independent pre-
dictor of mortality. Boutou et al also conducted a retrospec-
tive study to evaluate the association between anemia and 
survival in stable COPD outpatients.7 Of a total 294 COPD 
patients, 46 (15.6%) had anemia. Anemia was an independent 
predictor of mortality (HR 1.87, 95% CI, 1.06–3.29) and was 
associated with shorter median survival.
The association between anemia and mortality in hospital-
ized COPD patients has been recently evaluated. Martinez-
Rivera et al reported that anemia and previous exacerbations 
were independent predictors of 1-year mortality in hospital-
ized COPD patients.6 Patients with anemia had a relative risk 
of death of 5.9 (95% CI, 1.9–18.9). Toft-Petersen et al simi-
larly reported that a lower hemoglobin level at admission was 
related to higher risk of long-term mortality after discharge.9 
Some studies have evaluated short-term mortality in anemic 
COPD patients with hospitalization. Rasmussen et al evalu-
ated the 90-day mortality among COPD patients who needed 
invasive mechanical ventilation.5 In these patients, anemia 
was associated with increased mortality, and the adjusted 
90-day mortality risk ratio was 2.6 (95% CI, 1.5–4.5). Ergan 
and Ergün also reported that anemia was a risk factor of 
in-hospital death in COPD patients requiring mechanical 
ventilation.8 In multivariate analysis, the odds ratio of anemia 
for hospital mortality was 3.99 (95% CI, 1.4–11.4).
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Previous studies have reported the prevalence of anemia 
in COPD ranging from 7.5% to 32.7%.3 The prevalence in our 
study was 6.6%. Anemia reflects chronic illness and burden 
of disease, and our cohort included a relatively healthy popu-
lation who regularly underwent the national health screening 
examination. The patients included in this study were newly 
diagnosed patients with COPD and probably milder than other 
cohorts previously reported. Therefore, the prevalence in our 
study might be lower than in other studies. Interestingly, 
other studies on stable outpatients with COPD have reported 
a prevalence of anemia ranging from 15.6% to 17.1%.7,18
Although several studies have shown that anemia in 
COPD is related to increased mortality, to our knowledge, 
there are no studies that evaluated the association between 
anemia and long-term mortality of COPD in the general 
population. Our study also included a larger number of 
COPD patients with long-term follow-up compared with 
previous studies. Our results are significant in that anemia 
increases mortality even in the general COPD population who 
do not require oxygen therapy, hospitalization, or frequent 
healthcare use. We also showed that even a mild decrease in 
hemoglobin increased the risk of death. Toft-Petersen et al 
reported similar results.9 They showed that a decrease in 
hemoglobin by only 1 g/dL compared with the normal value 
had an HR for death of 1.37 (95% CI, 1.15–1.64) in males 
and 1.28 (95% CI, 1.06–1.53) in females.
Our study has some limitations. First, we could not use 
spirometry data, but used only ICD-10 codes and medications 
for COPD diagnosis. However, this working definition has 
been utilized and validated in many previous studies.10–13 We 
could not also use an individual’s medical history or symptoms 
that might be helpful for COPD diagnosis. Second, confound-
ing factors could have affected the mortality. COPD mortality 
is associated with various factors. We attempted to control 
for possible confounders, such as socioeconomic status, CCI, 
BMI, and smoking; however, other factors were not examined. 
Especially, we did not include the important comorbidities of 
COPD that may have influenced mortality. Moreover, ane-
mia has numerous causes that may be confounders, and we 
could not exclude patients with comorbidity associated with 
anemia. Third, this is a retrospective observational study and 
so could involve missing data or follow-up loss. However, in 
the NHIS database, every detail of healthcare utilization was 
recorded without any missing data. Moreover, since national 
insurance is mandatory by law, almost the entire population 
in Korea can be followed in the NHIS database without loss. 
This advantage of the NHIS database can increase the value 
of the results obtained in this study.
Conclusion
Our large population-based study showed that anemia was 
associated with increased long-term mortality of COPD. 
Even mild anemia was related to a significantly increased 
risk of death. Hemoglobin level was well correlated with risk 
of death. More studies are needed to prospectively evaluate 
the effects of anemia on COPD mortality.
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